I found the first page of this article provided a good and fairly understandable overview of where we are with chimeric antigen receptors (CARs) and in particular with the use of the T-cell receptor CAR-T). Much of the article is devoted to blood cancers, in particular B-cell cancers, with CLL specifically mentioned. "Since CD19 is found on the cell surface in most leukemias and lymphomas, but nowhere else in the body except for B-lineage cells, it is an attractive target for therapy. In addition, CD19 has been implicated in tumor survival, making it more likely to be present on—and less likely to be lost from—all tumor cells."
There's also some very encouraging news on progress towards overcoming the major disadvantage so far with CAR-T - the personalised and therefore expensive approach. "We are developing off-the-shelf T cells before the patient arrives at a treatment facility,” asserts Dr. Cooper. “This enables a biobank of T cells to be pre-prepared, which could be a one-time cost.”
Brad, thanks for your very kind words, but I really can't accept all that credit. Nick won the HU global admin of the year award last year, so I guess I had some good training .
The sunset photo turned out well thanks to a fortunate choice of camera which has a good sunset mode, plus the clouds that evening filtering out most of the sun's intensity. I've had enough experience with disappointing full moon photographs to appreciate what a fantastic job our eyes do in coping with such a huge dynamic range in light intensity in these situations.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
.
New "kid" on the therapy block
Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell CLL
Scientists hail autoimmune disease therapy breakthrough - implications for CLL patients?
